ArticleJournal of veterinary internal medicine2026
Effect of pimobendan on mitral annular dynamics and mitral regurgitation in dogs with myxomatous mitral valve disease as determined by cardiac computed tomography.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPimobendan might affect mitral annular dynamics (MAD) in dogs with myxomatous mitral valve disease (MMVD); in humans, alterations in MAD are known to increase the severity of mitral regurgitation (MR). HYPOTHESIS/
objectivesTo investigate the short-term effect of pimobendan on MAD, severity of MR, and systemic arterial compliance in dogs with MMVD. ANIMALS: Twenty dogs with newly diagnosed ACVIM stage B2 MMVD.
methodsProspective, open-label, longitudinal study. All dogs underwent echocardiographic and cardiac computed tomographic (CCT) examinations before and 2 weeks after oral administration of pimobendan. Changes in MAD, leaflet-to-annulus index, left heart volumes, regurgitant volume/fraction, and aortic distensibility index were evaluated on CCT.
resultsAll dogs completed the study without major adverse events. Pimobendan decreased normalized end-systolic mitral annular area (mean difference of 1.38 cm2/m2; 95% CI, 0.79-1.97 cm2/m2; P < .001), aortoparietal distance (mean difference of 1.03 mm/kg1/3; 95% CI, 0.54-1.53 mm/kg1/3; P < .001), and intercommissural distance (mean difference of 0.75 mm/kg1/3; 95% CI, 0.44-1.06 mm/kg1/3; P < .001). Mean leaflet-to-annulus index increased (mean difference of 0.06; 95% CI, 0.02-0.09; P = .002). Changes in left ventricular end-diastolic and end-systolic volumes, left atrial end-diastolic and end-systolic volumes, regurgitant volume (mean reduction of 0.31 mL/kg; 95% CI, 0.13-0.5 mL/kg), and regurgitant fraction (mean reduction of 9.8%; 95% CI, 5.2%-14.3%) were detected (all P < .05) with administration of pimobendan. There was no detectable difference in aortic distensibility index (P = .6). CONCLUSIONS AND CLINICAL IMPORTANCE: Short-term pimobendan administration decreases MR severity by augmenting systolic contraction of the mitral annulus. The study provides new insight into the mechanism of action of pimobendan in dogs with MMVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.